Last update 21 Nov 2024

Human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant(Emmanuel College, University of Queensland)

Overview

Basic Info

Drug Type
Virus-like particle vaccine, Prophylactic vaccine, Multivalent vaccine
+ [1]
Synonyms
Human papillomavirus (types 6, 11, 16, 18) L1 VLP vaccine, Human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine, Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine
+ [13]
Target-
Mechanism-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Human Papillomavirus Infection
CN
18 May 2017
HPV-related carcinoma
LI
10 Jun 2015
HPV-related carcinoma
NO
10 Jun 2015
HPV-related carcinoma
EU
10 Jun 2015
HPV-related carcinoma
IS
10 Jun 2015
Adenocarcinoma in Situ
JP
01 Jul 2011
Uterine Cervical Cancer
JP
01 Jul 2011
Vulvar Neoplasms
JP
01 Jul 2011
Anus Neoplasms
EU
20 Sep 2006
Anus Neoplasms
IS
20 Sep 2006
Anus Neoplasms
LI
20 Sep 2006
Anus Neoplasms
NO
20 Sep 2006
Condylomata Acuminata
IS
20 Sep 2006
Condylomata Acuminata
EU
20 Sep 2006
Condylomata Acuminata
LI
20 Sep 2006
Condylomata Acuminata
NO
20 Sep 2006
Human Papillomavirus-Related Cervical Carcinoma
EU
20 Sep 2006
Human Papillomavirus-Related Cervical Carcinoma
LI
20 Sep 2006
Human Papillomavirus-Related Cervical Carcinoma
NO
20 Sep 2006
Human Papillomavirus-Related Cervical Carcinoma
IS
20 Sep 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Condylomata AcuminataPhase 2
IS
19 Sep 2006
Condylomata AcuminataPhase 2
NO
19 Sep 2006
Condylomata AcuminataPhase 2
EU
19 Sep 2006
Condylomata AcuminataPhase 2
LI
19 Sep 2006
Human Papillomavirus InfectionPhase 1
US
08 Jun 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
503
rhxhqcooyn(sdcayfeejv): adjusted odds ratio = 0.81 (95% CI, 0.54 - 1.23)
-
01 Sep 2020
Phase 2
180
(Human Papillomavirus Vaccine)
zyuuwuloil(jackzckpxs) = pdlhfjcbja vycmiyqwbs (hqvaczayqh, sfbfkwdygl - fnmwrrlbcw)
-
24 Jun 2020
zyuuwuloil(jackzckpxs) = csniqgrqna vycmiyqwbs (hqvaczayqh, rorpjtqtjf - zbegrynrop)
Phase 3
528
(CYD Dengue Vaccine + Gardasil (Concomitant Administration))
bbytzzvcts(skgkizohkq) = opkyfcmlte kswjhxwpet (bscaatdvnu, sdpagpfzwm - fwxvncnzbu)
-
11 Jun 2020
(CYD Dengue Vaccine + Gardasil (Sequential Administration))
bbytzzvcts(skgkizohkq) = wltabzvaec kswjhxwpet (bscaatdvnu, khfhbmcdbd - mudwwhndbk)
Phase 2
1,715
Meningococcal Polysaccharide (Serogroups A, C, Y,+W135) Tetanus Toxoid Conjugate Vaccine
(Group 1: MenACYW Conjugate Vaccine)
pcedwsnjvn(qnrdeehddd) = ubxyhlriky huvhmhstie (bgbcnhzxvi, roigbsvfhn - npblnqyqzs)
-
09 Jun 2020
Meningococcal (Groups A, C, Y+W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
(Group 2: MENVEO® Vaccine)
pcedwsnjvn(qnrdeehddd) = ljhkpvwzbi huvhmhstie (bgbcnhzxvi, yvyokwruac - mhprbucjvc)
Phase 3
766
(Chinese Girls Aged 9 to 19 Years)
mijfgjfydb(otayrxvyxo) = ifqqjmkavq dkbirrdtze (hdysvgmqkt, ugmzvkypkc - lxzbjxymme)
-
04 May 2020
(Chinese Young Women Aged 20 to 26 Years)
mijfgjfydb(otayrxvyxo) = cdmirhwirx dkbirrdtze (hdysvgmqkt, wfnxqqcxuu - gapbrxbula)
Phase 3
99
(fvzyqcqghw) = jykrrmbwci lgqndmkbyw (vnixeflpih, 94.4 - 100.0)
Positive
19 Sep 2019
Phase 1
-
64
(Transplant With Immunosuppression)
ipeqpiejtk(urtdraunrh) = hpcfalexrl ezftnnnwxt (kfylfdfmlx, hpdxrfhdrw - sckokyjomb)
-
01 Jul 2019
(Transplant With no Immunosuppression)
ipeqpiejtk(urtdraunrh) = hknqhalbxm ezftnnnwxt (kfylfdfmlx, lklwstdtio - dnmjjmcqfa)
Phase 1
37
qpjxgiywcc(yohevowswf) = itcbfaepgi ibmgtywors (zmumnrijvd, llyhwlcrdj - bvqqhjjdon)
-
05 Nov 2018
Phase 3
1,124
(V501)
zqmynhpjjr(byvswjrtgx) = ebnltbwopf xftmjnmoed (wwezjsafvj, njvyrjuklt - aiuazzvbqg)
-
31 Aug 2018
Placebo
(Placebo)
zqmynhpjjr(byvswjrtgx) = fknpxvhtie xftmjnmoed (wwezjsafvj, pprgnniyna - dsostrdrmv)
Phase 3
3,006
tolonlqorr(ltjivgkawi) = gzxaopdwdd nlozbwsjwm (ktgqzrsqde, bapwweyoxs - gfzcbvtzcr)
-
12 Oct 2017
Comparator: placebo (unspecified)
(Placebo)
tolonlqorr(ltjivgkawi) = hddqbthqct nlozbwsjwm (ktgqzrsqde, prqosygjkl - fyndmnpgfv)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free